We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Luminex Licenses Cystic Fibrosis Gene Patent from John Hopkins University
News

Luminex Licenses Cystic Fibrosis Gene Patent from John Hopkins University

Luminex Licenses Cystic Fibrosis Gene Patent from John Hopkins University
News

Luminex Licenses Cystic Fibrosis Gene Patent from John Hopkins University

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Luminex Licenses Cystic Fibrosis Gene Patent from John Hopkins University"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Luminex Corporation has announced that it has acquired a non-exclusive license from The Johns Hopkins University for the rights to use the university's patented cystic fibrosis genetic markers in the company's molecular diagnostic products sold in the United States.

Rights to use the genetic markers will be included with Tag-It™ cystic fibrosis products, which are available from Luminex's new division, Luminex Molecular Diagnostics (formerly Tm Bioscience), and extend to the company's distributors and end-user customers.

"These genetic markers from John Hopkins are an important element in advancing the diagnosis and monitoring of cystic fibrosis," said Jeremy Bridge-Cook, Vice President of Luminex Molecular Diagnostics. "We are pleased to be able to provide our customers and distributors with the rights to these markers as part of our Tag-It™ Cystic Fibrosis Kit."

The Tag-It™ Cystic Fibrosis Kit aids in newborn screening and confirmatory CF diagnostic testing in newborns and children and can determine CF carrier status in adults. The kit simultaneously screens for the 23 cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and 4 variants (polymorphisms), as recommended by the American College of Medical Genetics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG) in 2004. It also screens for 16 additional CFTR mutations prevalent in North America or the world.

The license from Johns Hopkins provides Tag-It™ CF Kit users and distributors rights to 4 mutations (549N, 551D, 553X, 559T) tested for in the kit and covers 2 mutations (553X and 551D) in the screening panel of 23 cystic fibrosis gene mutations recommended by ACMG and ACOG.

Advertisement